Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 12:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 415 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Cream Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia

NCT05332366
View directory record Official record
Conditions
Frontal Fibrosing Alopecia
Interventions
Delgocitinib cream, Delgocitinib cream vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 3 Interventional Results available

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)

NCT04845620
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
Roflumilast Cream 0.05%, Vehicle Cream
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
2 Years to 5 Years
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
71
States / cities
Birmingham, Alabama • Montgomery, Alabama • Gilbert, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD)

NCT02925793
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
DS107, Vehicle cream
Drug · Other
Lead sponsor
DS Biopharma
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Oct 20, 2026, 12:31 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

SWC for Treatment of Superficial Partial-Thickness Burns

NCT05877638
View directory record Official record
Conditions
Burn Wounds
Interventions
SynePure Wound Cleanser and Catasyn Advanced Technology Hydrogel, SILVADENE Cream 1% (silver sulfadiazine)
Device · Drug
Lead sponsor
Synedgen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 2 Interventional Results available

A Six Week Topical Cream Study for Subjects With Ichthyosis Vulgaris

NCT03173547
View directory record Official record
Conditions
Ichthyosis Vulgaris
Interventions
146-9251 cream, Vehicle cream
Drug
Lead sponsor
Crown Laboratories, Inc.
Industry
Eligibility
12 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
San Diego, California • Plainfield, Indiana • Metairie, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 20, 2026, 12:31 AM EDT
Terminated Early Phase 1 Interventional

Six Months Evaluation of Next Science Acne Creams on Facial Acne in Adult Females.

NCT03106766
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Acne cream 2X, Acne cream 1X
Drug
Lead sponsor
Next Science TM
Industry
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 2 Interventional Results available

Topical ASC-J9 Cream for Acne

NCT01289574
View directory record Official record
Conditions
Acne
Interventions
ASC-J9
Drug
Lead sponsor
AndroScience Corp
Industry
Eligibility
12 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 1, 2014 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (26)

NCT02608476
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CB-03-01 cream, 1%, Vehicle cream
Drug
Lead sponsor
Cassiopea SpA
Industry
Eligibility
9 Years and older
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 1 Interventional

The Effect of Ablation of Epidermal Nerve Fibers Using Capsaicin Cream

NCT01883102
View directory record Official record
Conditions
Pain
Interventions
Capsaicin 0.1%, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
39 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 3 Interventional Results available

Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts

NCT00674739
View directory record Official record
Conditions
Genital Warts
Interventions
Imiquimod, 3.75% imiquimod cream, placebo cream
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
12 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
30
States / cities
Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated May 24, 2011 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Vaginal and Urinary Microbiome Trial

NCT02869165
View directory record Official record
Conditions
Atrophic Vaginitis, Menopause, Recurrent Urinary Tract Infections
Interventions
Conjugated equine estrogen topical cream, Apricot kernel oil
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 20, 2026, 12:31 AM EDT
Terminated Phase 4 Interventional Results available

Treatment w/ Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma

NCT00669071
View directory record Official record
Conditions
Melasma
Interventions
Fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%, Cetaphil® Moisturizing Cream as Inactive Control
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 74 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
La Jolla, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Oct 20, 2026, 12:31 AM EDT
Withdrawn Phase 2 Interventional

Topical Steroids & Bacterial Decolonization for Radiation Dermatitis

NCT05505214
View directory record Official record
Conditions
Radiation Dermatitis
Interventions
Bacterial decolonization, Mometasone furoate 0.1% cream, Bacterial decolonization and Mometasone furoate 0.1% cream
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 3 Interventional Results available

Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer

NCT00296036
View directory record Official record
Conditions
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
pyridoxine hydrochloride, urea/lactic acid-based topical cream, placebo
Dietary Supplement · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
231
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 148 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis

NCT00361881
View directory record Official record
Conditions
Herpes Labialis
Interventions
ME-609, acyclovir in ME-609 vehicle, Vehicle
Drug
Lead sponsor
Medivir
Industry
Eligibility
18 Years and older
Enrollment
1,443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Mt. Pleasant, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 18, 2008 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 3 Interventional

Bioequivalence Study to Compare Sol-Gel Technologies' 5-FU Cream With Efudex® (5-FU) Cream

NCT03727074
View directory record Official record
Conditions
Actinic Keratosis (AK)
Interventions
5-FU Cream, Efudex®, Vehicle
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cerritos, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 2 Interventional Results available

Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa

NCT02014376
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
SD-101 dermal cream (3%), SD-101 Dermal Cream (6%), Vehicle (SD-101 0%)
Drug
Lead sponsor
Scioderm, Inc.
Industry
Eligibility
6 Months and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
7
States / cities
Palo Alto, California • Chicago, Illinois • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT02260986
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Placebo (for Dupilumab), Topical Corticosteroid (TCS)
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
50
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Oct 20, 2026, 12:31 AM EDT
Not listed Not applicable Interventional

Feasibility Study of Barrier Enhancement for Eczema Prevention

NCT01142999
View directory record Official record
Conditions
Eczema
Interventions
Sunflower oil, Control group, Aquaphor ointment, Cetaphil cream
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
1 Minute to 6 Months
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 5, 2011 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Determine the Therapeutic Benefit of an OTC Cream on Dry, Itchy Skin of Adults and Children With Eczema

NCT02691507
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
EpiCeram Skin Barrier Emulsion, Experimental Product 1% Colloidal Oatmeal Balm
Device · Drug
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
12 Years and older
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Colorado Springs, Colorado • Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 2 Interventional

A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis

NCT02340234
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab, Placebo, TCS Cream
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Oct 20, 2026, 12:31 AM EDT
Withdrawn Phase 1 Interventional

Examination of Whether Host Preconditioning Modifies Short-term Transplant Survival

NCT01960764
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Pre-Treatment with Dial liquid antibacterial soap, Control
Drug · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 2 Interventional Results available

Topical Perillyl Alcohol in Treating Patients With Sun Damaged Skin and Actinic Keratoses

NCT00608634
View directory record Official record
Conditions
Precancerous Condition
Interventions
perillyl alcohol, placebo
Drug · Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 1, 2015 · Synced Oct 20, 2026, 12:31 AM EDT
Completed Phase 3 Interventional

Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis

NCT02896101
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus Cream, 1%, Elidel® (pimecrolimus) Cream, Placebo of Pimecrolimus Cream, 1%
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
12 Years and older
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
27
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 20, 2026, 12:31 AM EDT